Previous Close | 2.0200 |
Open | 2.0000 |
Bid | 1.8100 x 1000 |
Ask | 1.9800 x 900 |
Day's Range | 1.9100 - 2.0000 |
52 Week Range | 1.5100 - 25.0400 |
Volume | |
Avg. Volume | 396,783 |
Market Cap | 44.655M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2590 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for EVAX
COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the Company has identified Gonorrhea as its second bacterial target for treatment with the Company’s EVX-B2 vaccine product candidate. As its second bacterial target, Evaxion has chosen to develop a prophylactic vaccine against Gonorrhea, a sexually transmit
Evaxion Biotech A/S (NASDAQ: EVAX) has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022. We currently have two product candidates in the DNA technology platform, EVX-02, and EVX-03. Based on preclinical results, the company has decided to move EVX-03 in an upcoming clinical trial in a new indication. EVX-03 is optimized with an APC-targeting unit (Antigen-Presenting Cell), which has shown promising pr
COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022. We currently have two product candidates in our DNA technology platform, EVX-02, and EVX-03. Based on ver